Literature DB >> 16541304

The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.

M Salhab1, M J Reed, W Al Sarakbi, W G Jiang, K Mokbel.   

Abstract

INTRODUCTION: There is substantial evidence that breast cancer tissue contains all the enzymes responsible for the local biosynthesis of estrogens from circulating precursors. The cytochrome P-450 aromatase enzyme complex is responsible for the conversion of C19 androgens to estrogens and 17-beta-hydroxysteroid dehydrogenase (17-I(2)-HSD) type 1 catalyses the inter-conversion of estrone to the biologically more potent estradiol. The gene encoding for the cytochrome P-450 aromatase is known as CYP19 (15q21.2). It is well established that increased exposure to local estrogens is an important risk factor in the genesis and growth of breast cancer. The aim of this study is to investigate the relationship between CYP19 and 17-beta-HSD type 1A mRNA expression and clinico-pathological parameters of human breast cancer.
METHODS: One hundred and twenty seven tumor tissues and 33 normal tissues were analyzed. The levels of transcription of CYP19 and 17-beta-HSD type 1 were determined using real-time quantitative PCR. The mRNA expression was normalized against CK19. Levels of expression were analyzed against tumorâ's stage, grade, nodal status, local relapse, distant metastasis and survival over a 120A months follow up period. In addition, the levels were analyzed against estrogen receptor (ER) and HER1-4 status.
RESULTS: Overall, high tumor levels of mRNA expression of CYP19 and 17-beta-HSD type 1 correlated with poor survival (p=0.0105 and p=0.0182, respectively). Increased levels of CYP19 mRNA expression positively correlated with disease progression as levels were significantly higher in samples of patients who had distant metastasis and local recurrence and/or died of breast related causes when compared to those who were disease free for >10 years (p=0.0015). We also observed higher levels of CYP19 mRNA in tumor samples compared to normal breast tissue. However, this reached statistical significance only when comparing grade 1 tumors with normal tissue (p=0.01). There was no correlation between CYP19á mRNA expression and tumor stage, lymph node status and tumor grade. There was however a trend for a positive correlation between CYP19 and ER mRNA expressions (p=0.06). No significant difference in 17-beta-HSD type 1 expression between normal and cancerous tissues was observed. In tumor samples, we observed an increase in levels correlating with tumor's grade. This correlation was statistically significant when we compared grade 1 with grade 2 and grade 1 with grade 3 (p=0.0031 and 0.0251, respectively).
CONCLUSION: Our study shows that higher levels of the enzymes responsible for the local biosynthesis of estrogens especially aromatase are associated with a poor clinical outcome in patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541304     DOI: 10.1007/s10549-006-9198-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  7,8-Dihydroxycoumarin exerts antitumor potential on DMBA-induced mammary carcinogenesis by inhibiting ERα, PR, EGFR, and IGF1R: involvement of MAPK1/2-JNK1/2-Akt pathway.

Authors:  Abhishek Kumar; Priyashree Sunita; Shivesh Jha; Shakti P Pattanayak
Journal:  J Physiol Biochem       Date:  2018-02-12       Impact factor: 4.158

2.  Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer.

Authors:  Henriette E Meyer zu Schwabedissen; Rommel G Tirona; Cindy S Yip; Richard H Ho; Richard B Kim
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

3.  Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression.

Authors:  Jiaqi Fu; Amy M Weise; Josie L Falany; Charles N Falany; Bryan J Thibodeau; Fred R Miller; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Breast Cancer Res Treat       Date:  2009-03-24       Impact factor: 4.872

4.  17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.

Authors:  Juliette A Aka; Mouna Zerradi; François Houle; Jacques Huot; Sheng-Xiang Lin
Journal:  Breast Cancer Res       Date:  2012-06-12       Impact factor: 6.466

5.  Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.

Authors:  Keya De Mukhopadhyay; Zhao Liu; Abhik Bandyopadhyay; Nameer B Kirma; Rajeshwar R Tekmal; Shui Wang; Lu-Zhe Sun
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

6.  Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.

Authors:  Andrea Friesenhengst; Tamara Pribitzer-Winner; Heidi Miedl; Katharina Pröstling; Martin Schreiber
Journal:  Horm Cancer       Date:  2018-01-23       Impact factor: 3.869

7.  Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.

Authors:  Marc A Bollet; Alexia Savignoni; Leanne De Koning; Carine Tran-Perennou; Catherine Barbaroux; Armelle Degeorges; Brigitte Sigal-Zafrani; Geneviève Almouzni; Paul Cottu; Rémy Salmon; Nicolas Servant; Alain Fourquet; Patricia de Cremoux
Journal:  Breast Cancer Res       Date:  2009-07-28       Impact factor: 6.466

8.  Influence of CYP19A1 gene expression levels in women with breast cancer: a systematic review of the literature.

Authors:  Maria da Conceição Barros-Oliveira; Danylo Rafhael Costa-Silva; Alesse Ribeiro Dos Santos; Renato Oliveira Pereira; José Maria Soares-Júnior; Benedito Borges da Silva
Journal:  Clinics (Sao Paulo)       Date:  2021-06-14       Impact factor: 2.365

9.  CYP19A1 gene expression in the peripheral blood of Brazilian women with breast cancer relapse.

Authors:  Maria da Conceição Barros-Oliveira; Danylo Rafhael Costa-Silva; Larysse Cardoso Campos-Verdes; Renato de Oliveira Pereira; Rozirene Araújo Silva; Paulo de Tarso Moura-Borges; Emerson Brandão Sousa; André Luiz Pinho-Sobral; Pedro Vitor Lopes-Costa; Alesse Ribeiro Dos Santos; Ione Maria Ribeiro Soares-Lopes; Jackeline Lopes Viana; Mariella de Almeida Melo; Fidelis Manes Neto; Eid Gonçalves Coelho; Maria do Socorro Pires E Cruz; Vladimir Costa-Silva; Luiz Henrique Gebrim; Benedito Borges Da Silva
Journal:  BMC Cancer       Date:  2020-05-27       Impact factor: 4.430

Review 10.  The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy.

Authors:  Giorgio Dell'Acqua; Aleksander Richards; M Julie Thornton
Journal:  Nutrients       Date:  2020-11-18       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.